CHATSWORTH, Calif., March 11, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it will be presenting at Sidoti & Company's 14th Annual Emerging Growth Institutional Investor Forum at 1:30 p.m. Eastern time on Wednesday, March 24, 2010 at The Grand Hyatt Hotel in New York City. Cesar Garcia, IRIS Chairman, President and Chief Executive Officer, will present an overview of the Company followed by Q&A. A copy of the presentation will be available on the Company's web site at www.proiris.com.
CHATSWORTH, Calif., March 1, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), reflecting improved instruments sales and record sales of consumables and service, today announced revenue of $26.5 million for the fourth quarter ended December 31, 2009, relatively flat from revenue of $26.7 in the prior year fourth quarter. Net income in the 2009 fourth quarter of $1.9 million, or $0.11 per diluted share, which included a one-time accrual of $0.5 million, or $0.02 per diluted share, for payroll taxes attributable to the exercise of stock options, compares with net income of $3.4 million, or $0.18 per diluted share, in the year ago period, which included a one-time gain of $1.2 million, or $0.04 per diluted share, related to the manufacturing transition and licensing agreement signed with IDEXX Laboratories in December 2008. Diluted weighted average shares outstanding for the three months ended December 31, 2009 and 2008, were 18.0 million and 18.5 million, respectively.
CHATSWORTH, Calif., Feb. 25, 2010 -- IRIS International Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has entered into a first-time three-year sales and service supply agreement with HealthTrust Purchasing Group, LP (HealthTrust), a leading national group purchasing organization (GPO).
CHATSWORTH, Calif., Feb. 3, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), will release its fourth quarter and year-end 2009 financial results after the close of trading on Monday, March 1, 2010. IRIS management will also host a conference call and webcast that day at 4:30 P.M. Eastern Time, to discuss the fourth quarter results, as well as provide a general business update, including a progress report on its NADiA(r) ProsVue(tm) ultra sensitive prostate-specific antigen diagnostic assay and its iChem(r)VELOCITY(tm) urine chemistry analyzer new product initiatives.
CHATSWORTH, Calif., Jan. 20, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its Board of Directors has approved an amendment to the Company's by-laws to adopt a majority vote standard for election of directors, beginning with the next election of directors at the Company's Annual Meeting of Stockholders in May.
CHATSWORTH, Calif., Jan. 19, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, has entered into a strategic partnership with Digital Images Diagnostic (China), Ltd.
CHATSWORTH, Calif., Jan. 12, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it had completed the purchase at book value of certain assets relating to the current distribution of Iris' products in the UK and Germany by the company's European distributor, IL UK and IL Germany of the Werfen Group. The assets purchased from IL UK and IL Germany consist primarily of customer leases related to the installed base of approximately 50 iQ(R)200 IRIS instruments and service contracts in those countries, which were valued at $840,000 as December 31, 2009.
CHATSWORTH, Calif., Jan. 5, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has elected Rick Timmins, a highly seasoned executive with more than 30 years of senior finance experience, to its Board of Directors and as a member of the Audit Committee, increasing the number of independent directors to seven.
CHATSWORTH, Calif., Dec. 17, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has appointed David W. Gates, Ph.D., to the newly-created position of Vice President, Quality and Regulatory Affairs. Dr. Gates' primary focus will be the formulation and implementation of regulatory strategies for all company units, including Iris Diagnostics, Iris Molecular Diagnostics (IMD) and Iris Sample Processing (ISP) business units, as well as overseeing all U.S. and international regulatory filings, in support of the advancement of the Company's existing and emerging product pipeline.
CHATSWORTH, Calif., Dec. 14, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that management will host a series of one-on-one meetings with analysts and fund managers on Wednesday, January 13, 2010, to be held at the Hilton San Francisco, 333 O'Farrell Street, San Francisco, Ca. The full day of meetings is being organized alongside the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.
CHATSWORTH, Calif., Nov. 19, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar Garcia will present an overview of the Company at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1, 2009 at 2:30 p.m. Eastern time at the New York Palace Hotel in New York City.
CHATSWORTH, Calif., Nov. 17, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer and marketer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that its Sample Processing Division has initiated shipments of its new StatSpin(R) OvaTube(TM) System for use in veterinary hospitals, clinics and reference laboratories to process fecal samples for the detection of ova and parasites.
CHATSWORTH, Calif., Nov. 11, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has appointed Lawrence J. Blecka, Ph.D., a senior executive with 30 years experience in medical device, diagnostics and biotechnology companies ranging from Fortune 500 to start-ups, as Vice President, Research and Development. Dr. Blecka will be responsible for overseeing all research and development of the Iris Diagnostics division, in support of the advancement of the Company's existing and emerging product pipeline.
CHATSWORTH, Calif., Oct. 27, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), bolstered by record contributions from sales of consumables and service and improved cost efficiencies, today announced third quarter operating income increased 7% to $2.3 million and net profits increased 18% to $1.9 million, or $0.11 per diluted share, the highest in any third quarter period, despite a 5% decline in overall revenue to $22.2 million as a result of lower U.S. instrument sales, for the third quarter ended September 30, 2009. This compares with operating income of $2.2 million and net earnings of $1.6 million, or $0.09 per diluted share, on revenue of $23.4 million in the prior year third quarter. Diluted weighted average shares outstanding for the three months ended September 30, 2009 and 2008, were 17.9 million and 18.8 million, respectively.
CHATSWORTH, Calif., Oct. 26, 2009 -- IRIS International, Inc. (Nasdaq:IRIS) announced today that it has received Institutional Review Board (IRB) approvals from Duke University Medical Center, Memorial Sloan Kettering Cancer Institute, Eastern Virginia Medical School and the University of Washington Medical Center to immediately begin a multi-center 300 patient retrospective randomized clinical study utilizing its NADiA(TM) ProsVue(TM) ultra sensitive prostate-specific antigen diagnostic assay.
CHATSWORTH, Calif., Oct. 22, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chief Financial Officer, Peter L. Donato, will present an overview of the Company at The Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009, at 1:00 p.m. Eastern time at the Waldorf Astoria Hotel in New York City.
CHATSWORTH, Calif., Sept. 22, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has signed a letter of intent to acquire from its European distributor, The Werfen Group, assets relating to its current distribution of IRIS' products in the UK and Germany. The assets to be purchased consist primarily of customer leases for installed IRIS instruments and service contracts, valued at inventory book value. The parties presently are negotiating a definitive acquisition agreement, and IRIS expects to consummate the acquisition at the end of December 2009.
CHATSWORTH, Calif., Sept. 10, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar Garcia will present an overview of the Company at the UBS annual Global Life Sciences Conference at 1:00 p.m. Eastern time on Tuesday, Sept. 22, 2009 at the Grand Hyatt Hotel in New York City.
CHATSWORTH, Calif., Aug. 20, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, has entered into a distribution agreement with Fujirebio Inc., one of the largest in vitro diagnostics (IVD) companies in Japan. The two companies made the announcement today.
CHATSWORTH, Calif., Aug. 3, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar Garcia will present an overview of the Company at the Canaccord Adams 29th Annual Global Growth Conference at 11:00 a.m. Eastern time on Thursday, August 13, 2009 at the Intercontinental Hotel in Boston, Mass.
CHATSWORTH, Calif., July 30, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced revenue of $22.3 million for the second quarter ended June 30, 2009, a decrease of 6% from revenue of $23.8 million in the year ago second quarter. Net income for the 2009 second quarter was $1.0 million, or $0.06 per share, compared with $2.2 million, or $0.12 per share in the year ago period.
CHATSWORTH, Calif., July 21, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that, ahead of its planned analysts breakfast briefing tomorrow, Wednesday, July 22 at the AACC 2009 Annual Meeting and Clinical Lab Expo in Chicago, it is pre-releasing selected preliminary results and providing an update on operations for the second quarter ended June 30, 2009.
CHATSWORTH, Calif., June 29, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that IRIS senior management, led by Cesar Garcia, Chairman and CEO, will host a financial analyst breakfast briefing and presentation on Wednesday, July 22, 2009, in conjunction with the American Association for Clinical Chemistry (AACC) 2009 Annual Meeting and Clinical Lab Exposition in Chicago, IL.
CHATSWORTH, Calif., June 18, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it is the winner of the fourth annual Supplier Pinnacle Award presented by Premier Purchasing Partners, LP, the group purchasing unit of the Premier healthcare alliance.
CHATSWORTH, Calif., June 2, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar M. Garcia will present an overview of the Company at the 6th Annual Craig-Hallum Institutional Investor Conference at 2:00 p.m. Central time on Thursday, June 11, 2009 at the Radisson Plaza Hotel in Minneapolis, Minnesota.
CHATSWORTH, Calif., May 27, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, has elected Dr. Beth Y. Karlan to its Board of Directors, it was announced today by Cesar M. Garcia, Chairman, President and Chief Executive Officer. "The addition to our Board of such a distinguished cancer scientist and physician as Dr. Karlan underscores our commitment not only to our core business but to our belief in the importance of our NADiA(r) (nucleic acid detection immunoassay) technology platform with applications in early detection of relapse in prostate cancer, AIDS and other diseases," said Mr. Garcia. "Dr. Karlan's expertise in early detection of cancer, genetics and biomarkers which form a molecular signature that predicts response to therapy and survival, makes her an ideal corporate Director for Iris as we advance in our research, development and commercialization of our molecular diagnostics and advanced hematology platforms. She brings unique skills and an impressive record of clinical and educational contributions to the advancement of cancer treatment and detection."
CHATSWORTH, Calif., May 26, 2009 -- In a release issued earlier today by IRIS International, Inc. (Nasdaq:IRIS) under the same headline, please note the addition of Stephen E. Wasserman as a board of director. The updated release follows.
CHATSWORTH, Calif., May 26, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, "following resumption of full-scale shipments of its new iChem(r)Velocity(tm) Automated Urine Chemistry Analyzers to the international market, remains on track for achieving its previously announced guidance for the current second quarter ending June 30, and for the full year ending December 31, 2009," Cesar Garcia, Chairman and Chief Executive Officer, told shareholders attending its Annual Meeting held here on Friday.
CHATSWORTH, Calif., May 21, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that following the validation of previously announced design improvements, it has resumed full-scale shipments of its new iChem(r)Velocity(tm) Automated Chemistry Analyzers to the International Market.
CHATSWORTH, Calif., May 4, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that its IRIS Diagnostics Business Unit has been honored with a Group Buy Excellence Award and Gold Vendor Award by MedAssets Supply Chain Systems, one of the largest U.S. group purchasing and supply chain organizations.
CHATSWORTH, Calif., April 29, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced revenue of $21.6 million for the first quarter ended March 31, 2009, which is the same as the year ago first quarter revenue. Net income for the 2009 quarter was $1.4 million, or $0.08 per share, compared with $1.8 million, or $0.10 per share in the year ago period.
CHATSWORTH, Calif., April 3, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), this week proudly celebrates 30 years of excellence as a leading in vitro diagnostics company, having evolved from its founding in 1979 as a fledgling research and development stage company with no revenue, to a company today approaching $100 million in sales and more than 300 employees serving the needs of urinalysis across the globe, delivering iQ brand recognized system automation and improving efficiency and quality at laboratories in more than 60 countries, Cesar Garcia, Chairman, President and Chief Executive Officer, announced today.
CHATSWORTH, Calif., March 17, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that current IRIS director Edward F. Voboril has been appointed new independent lead director, replacing Richard H. Williams who will leave the IRIS Board of Directors as of the Company's next annual meeting, as previously announced.
CHATSWORTH, Calif., March 11, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it will be presenting at Sidoti & Company's 13th Annual Emerging Growth Institutional Investor Forum at 11:00 a.m. Eastern time on Wednesday, March 25, 2009 at The Grand Hyatt Hotel in New York City. Peter Donato, IRIS Corporate Vice President and Chief Financial Officer, will present an overview of the Company followed by Q&A. A copy of the presentation will be available on the Company's web site at www.proiris.com.
